Homepage Top Section2

BenevolentAI is clinical-stage artificial intelligence (AI) enabled drug discovery company, while DNDi) is a not-for-profit research and development (R&D) organisation with focus on neglected diseases., The company focuses

Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are

As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other

The clinical trial is designed for assessing GRC 54276’s tolerability and safety as a monotherapy, as well as in combination with checkpoint inhibitors in these patients. GRC 54276

Upon receiving approval, the human monoclonal antibody Dupixent will be the first medicine available in the US for the treatment of eosinophilic esophagitis (EoE). It is designed to

The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to

As part of the collaboration, the companies will use Nurosene’s core AI tools, NetraHealthAtlas, to speed up the drug discovery process. NetraHealthAtlas is designed to produce insights regarding

Enjaymo is intended to reduce the need for red blood cell transfusion caused due to hemolysis in CAD patients. The drug is a humanised monoclonal antibody that selectively

As part of the collaboration, Janssen will provide its antibodies and Mersana will apply its Dolasynthen platform and expertise for the discovery of the new ADC product candidates.